Xtant Medical Announces Commercial Launch of its Next-Generation nanOss Strata™ Synthetic Bone Graft
XTNTnanOss Strata™ is designed to more closely mimic the structure of human bone, increase the graft's surface area, improve osteoconductivity and enhance the stimulation of cellular activity BELGRADE, Mont., Dec. 11, 2025 /PRNewswire/ -- Xtant Medical Holdings, Inc. (NYSE American: XTNT), a...
Xtant Medical Completes Sale of its Coflex® Assets and Paradigm OUS Businesses to Companion Spine
XTNTBELGRADE, Mont., Dec. 1, 2025 /PRNewswire/ -- Xtant Medical Holdings, Inc. (NYSE American: XTNT), a global medical technology company focused on surgical solutions for spinal and other orthopedic conditions, today announced that the company has completed its previously announced sale of...
Xtant Medical to Participate in the H.C. Wainwright 27th Annual Global Investment Conference
XTNT(XTNT) BELGRADE, Mont., Sept. 4, 2025 /PRNewswire/ -- Xtant Medical Holdings, Inc. (NYSE American: XTNT), a global medical technology company focused on surgical solutions for the treatment of spinal, orthopedic, and woundcare disorders, today announced that Sean Browne, CEO, and Scott Neils,...
Xtant Medical to Attend the CG 45th Annual Growth Conference
XTNTBELGRADE, Mont., Aug. 6, 2025 /PRNewswire/ -- Xtant Medical Holdings, Inc. (NYSE American: XTNT), a global medical technology company focused on surgical solutions for the treatment of spinal, orthopedic, and woundcare disorders, today announced that Sean Browne, CEO and Scott Neils, CFO...
Xtant Medical Hldgs Raises FY2025 Sales Guidance from $126.00M-$130.00M to $127.00M-$131.00M vs $128.35M Est
XTNTXtant Medical Hldgs Q1 Sales $32.90M Beat $31.20M Estimate
XTNTA Glimpse of Xtant Medical Hldgs's Earnings Potential
XTNTXtant Medical Announces Completion Of Secondary Private Sale Of 73.1M Shares By Funds Affiliated With OrbiMed Advisors; Co. Also Says Expects Prelim. Q1 Revenue $32.8M-$33.1M, Representing 18-19% Growth YoY Driven By Orthobiologics And Licensing Revenue
XTNTXtant Medical Hldgs Sees FY2025 Revenue of $126.000M-$130.000M vs $132.85M Est
XTNTXtant Medical Hldgs Q4 EPS $(0.02) Misses $(0.01) Estimate, Sales $31.51M Miss $31.80M Estimate
XTNTBTIG Maintains Buy on Xtant Medical Hldgs, Raises Price Target to $3
XTNTXtant Medical Appoints Scott Neils As Chief Financial Officer
XTNT